Possible application of Akkermansia muciniphila in stress management.

Microbiome research reports Pub Date : 2024-09-10 eCollection Date: 2024-01-01 DOI:10.20517/mrr.2023.81
Agata Misera, Wojciech Marlicz, Albert Podkówka, Igor Łoniewski, Karolina Skonieczna-Żydecka
{"title":"Possible application of <i>Akkermansia muciniphila</i> in stress management.","authors":"Agata Misera, Wojciech Marlicz, Albert Podkówka, Igor Łoniewski, Karolina Skonieczna-Żydecka","doi":"10.20517/mrr.2023.81","DOIUrl":null,"url":null,"abstract":"<p><p><i>Akkermansia muciniphila</i> (<i>A. muciniphila</i>) is a promising candidate bacterium for stress management due to its beneficial effects on the microbiota-gut-brain axis (MGBA). As a well-known mucin-degrading bacterium in the digestive tract, <i>A. muciniphila</i> has demonstrated significant benefits for host physiology. Recent research highlights its potential in treating several neuropsychiatric disorders. Proposed mechanisms of action include the bacterium's outer membrane protein Amuc_1100 and potentially its extracellular vesicles (EVs), which interact with host immune receptors and influence serotonin pathways, which are crucial for emotional regulation. Despite its potential, the administration of probiotics containing <i>A. muciniphila</i> faces technological challenges, prompting the development of pasteurized forms recognized as safe by the European Food Safety Authority (EFSA). This review systematically examines the existing literature on the role of <i>A. muciniphila</i> in stress management, emphasizing the need for further research to validate its efficacy. The review follows a structured methodology, including comprehensive database searches and thematic data analysis, to provide a detailed understanding of the relationship between stress, microbiota, and <i>A. muciniphila</i> therapeutic potential.</p>","PeriodicalId":94376,"journal":{"name":"Microbiome research reports","volume":"3 4","pages":"48"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11684984/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Microbiome research reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20517/mrr.2023.81","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Akkermansia muciniphila (A. muciniphila) is a promising candidate bacterium for stress management due to its beneficial effects on the microbiota-gut-brain axis (MGBA). As a well-known mucin-degrading bacterium in the digestive tract, A. muciniphila has demonstrated significant benefits for host physiology. Recent research highlights its potential in treating several neuropsychiatric disorders. Proposed mechanisms of action include the bacterium's outer membrane protein Amuc_1100 and potentially its extracellular vesicles (EVs), which interact with host immune receptors and influence serotonin pathways, which are crucial for emotional regulation. Despite its potential, the administration of probiotics containing A. muciniphila faces technological challenges, prompting the development of pasteurized forms recognized as safe by the European Food Safety Authority (EFSA). This review systematically examines the existing literature on the role of A. muciniphila in stress management, emphasizing the need for further research to validate its efficacy. The review follows a structured methodology, including comprehensive database searches and thematic data analysis, to provide a detailed understanding of the relationship between stress, microbiota, and A. muciniphila therapeutic potential.

嗜粘菌在应激管理中的应用前景。
由于其对微生物-肠-脑轴(MGBA)的有益作用,嗜粘杆菌(a.m uiniphila)是一种有希望用于应激管理的候选细菌。作为一种众所周知的消化道黏液降解细菌,嗜粘杆菌已被证明对宿主生理有显著的益处。最近的研究强调了它在治疗几种神经精神疾病方面的潜力。被提出的作用机制包括细菌的外膜蛋白Amuc_1100及其潜在的细胞外囊泡(ev),它们与宿主免疫受体相互作用并影响血清素通路,这对情绪调节至关重要。尽管具有潜力,但含有嗜粘杆菌的益生菌的管理面临着技术挑战,促使欧洲食品安全局(EFSA)认可安全的巴氏灭菌形式的发展。本文系统地回顾了嗜粘液芽孢杆菌在应激管理中的作用,强调需要进一步的研究来验证其有效性。该综述采用结构化方法,包括全面的数据库检索和专题数据分析,以详细了解应激、微生物群和嗜粘杆菌治疗潜力之间的关系。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.80
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信